Feline aortic thromboemboli and the potential utility of thrombolytic therapy with tissue plasminogen activator.
Feline aortic thromboembolism is a common and devastating clinical condition for which there is presently no effective therapy. Thrombolytic therapy with tissue plasminogen activator represents a promising, relatively noninvasive method for resolution of the clinical syndrome. In clinical trials in man, tissue plasminogen activator is proving to have advantages over previously available thrombolytic agents. Previously available thrombolytic agents require intensive monitoring and commonly cause complications that entail large monetary and manpower costs to monitor and control. Being specific for thrombus-associated plasminogen, t-PA enables more safe and effective thrombolysis without the hazards previously associated with thrombolytic therapy. In cats with aortic thromboemboli, early clinical trials are promising with regard to acute thrombolytic efficacy but raise questions concerning the risks and benefits of therapy and will require more controlled studies. It is estimated that t-PA therapy for a cat with aortic thromboemboli will cost approximately +500 to +1500, including hospitalization and drugs. This compares favorably with what most veterinary clients are willing to spend for quality veterinary care. However, before we can look upon t-PA therapy as a useful therapeutic advance, we must consider the etiopathogenesis and probability of rethrombosis. The results of controlled studies have not been published, but it is generally considered that there is a high probability of recurrence in cats. Fifty per cent of cats treated with t-PA have rethrombosed despite aspirin therapy at the recommended dose of 25 mg per kg every third day. Finding a cure for feline myocardial diseases (cardiomyopathies) and/or an effective method for safely anticoagulating cats at risk would help justify the monetary and manpower costs associated with thrombolytic therapy.(ABSTRACT TRUNCATED AT 250 WORDS)